Published in Blood on March 18, 2010
Gaucher disease: clinical profile and therapeutic developments. Biologics (2010) 1.27
Imiglucerase in the treatment of Gaucher disease: a history and perspective. Drug Des Devel Ther (2012) 1.10
Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study. Orphanet J Rare Dis (2012) 1.06
Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. J Inherit Metab Dis (2012) 1.06
Glycosylation and functionality of recombinant β-glucocerebrosidase from various production systems. Biosci Rep (2013) 0.98
Revised recommendations for the management of Gaucher disease in children. Eur J Pediatr (2012) 0.98
Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase. Am J Hematol (2013) 0.97
The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patients. Orphanet J Rare Dis (2012) 0.89
Gaucher disease and cancer: concept and controversy. Int J Cell Biol (2011) 0.87
Velaglucerase alfa. Nat Rev Drug Discov (2010) 0.85
An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease. Core Evid (2012) 0.83
Effects of switching from a reduced dose imiglucerase to velaglucerase in type 1 Gaucher disease: clinical and biochemical outcomes. Haematologica (2012) 0.83
Long-term effectiveness of enzyme replacement therapy in children with Gaucher disease: results from the NCS-LSD cohort study. J Inherit Metab Dis (2014) 0.82
A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability. Genet Med (2013) 0.81
Gaucher disease. J Clin Exp Hepatol (2014) 0.80
Long-term effectiveness of enzyme replacement therapy in adults with Gaucher disease: results from the NCS-LSD cohort study. J Inherit Metab Dis (2014) 0.80
Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients. Orphanet J Rare Dis (2016) 0.79
Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model. Orphanet J Rare Dis (2014) 0.79
Seven-year safety and efficacy with velaglucerase alfa for treatment-naïve adult patients with type 1 Gaucher disease. Am J Hematol (2015) 0.79
Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials. Am J Hematol (2015) 0.75
Investigations on therapeutic glucocerebrosidases through paired detection with fluorescent activity-based probes. PLoS One (2017) 0.75
The impact of the immune system on the safety and efficiency of enzyme replacement therapy in lysosomal storage disorders. J Inherit Metab Dis (2016) 0.75
Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy. Core Evid (2016) 0.75
A phase 2 multi-center, open-label, switch-over trial to evaluate the safety and efficacy of Abcertin® in patients with type 1 Gaucher disease. J Korean Med Sci (2015) 0.75
Velaglucerase alfa in the treatment of Gaucher disease type 1. Clin Investig (Lond) (2011) 0.75
Modelling disease outbreaks in realistic urban social networks. Nature (2004) 14.54
ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science (2010) 4.67
HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab (2008) 4.34
Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest (2007) 3.89
Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation (2008) 2.98
AgBase: a unified resource for functional analysis in agriculture. Nucleic Acids Res (2006) 2.92
Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol (2009) 2.64
AgBase: a functional genomics resource for agriculture. BMC Genomics (2006) 2.53
Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) (2002) 2.51
The roles of different pathways in the release of cholesterol from macrophages. J Lipid Res (2007) 2.38
HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J Clin Invest (2006) 2.36
Genome-wide association identifies a susceptibility locus for coronary artery disease in the Chinese Han population. Nat Genet (2011) 2.32
Decreased atherosclerosis in low-density lipoprotein receptor knockout mice transplanted with Abcg1-/- bone marrow. Arterioscler Thromb Vasc Biol (2006) 2.29
National study of US emergency department visits for attempted suicide and self-inflicted injury, 1997-2001. Ann Emerg Med (2005) 2.20
High-density lipoprotein protects macrophages from oxidized low-density lipoprotein-induced apoptosis by promoting efflux of 7-ketocholesterol via ABCG1. Proc Natl Acad Sci U S A (2007) 2.18
ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet. J Clin Invest (2008) 2.16
Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus. J Biol Chem (2007) 2.07
Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med (2014) 2.01
Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. J Natl Cancer Inst (2007) 2.00
An antisense CAG repeat transcript at JPH3 locus mediates expanded polyglutamine protein toxicity in Huntington's disease-like 2 mice. Neuron (2011) 2.00
Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial. Lancet (2009) 1.87
US emergency department visits for alcohol-related diseases and injuries between 1992 and 2000. Arch Intern Med (2004) 1.82
Evaluation of refractive error measurements of the Wavescan Wavefront system and the Tracey Wavefront aberrometer. J Cataract Refract Surg (2003) 1.76
Regulation and mechanisms of macrophage cholesterol efflux. J Clin Invest (2002) 1.76
The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol (2007) 1.70
Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood (2011) 1.68
Angiotensin-converting enzyme-2 overexpression improves left ventricular remodeling and function in a rat model of diabetic cardiomyopathy. J Am Coll Cardiol (2012) 1.64
ATP-binding cassette transporter A7 enhances phagocytosis of apoptotic cells and associated ERK signaling in macrophages. J Cell Biol (2006) 1.63
Mesenchymal stem cells attenuate ischemic acute kidney injury by inducing regulatory T cells through splenocyte interactions. Kidney Int (2013) 1.60
Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease. Blood Cells Mol Dis (2012) 1.58
Mitral regurgitation progression following isolated coronary artery bypass surgery: frequency, risk factors, and potential prevention strategies. Eur J Cardiothorac Surg (2006) 1.55
Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol (2007) 1.53
Gene Ontology annotation quality analysis in model eukaryotes. Nucleic Acids Res (2008) 1.50
Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor. J Virol (2006) 1.49
Deficiency of ATP-binding cassette transporters A1 and G1 in macrophages increases inflammation and accelerates atherosclerosis in mice. Circ Res (2013) 1.47
Low-dose therapy trumps high-dose therapy again in the treatment of Gaucher disease. Blood (2006) 1.47
Optical coherence tomography and histologic measurements of nerve fiber layer thickness in normal and glaucomatous monkey eyes. Invest Ophthalmol Vis Sci (2007) 1.46
ATP-binding cassette transporters, atherosclerosis, and inflammation. Circ Res (2014) 1.46
Deficiency of ATP-binding cassette transporter B6 in megakaryocyte progenitors accelerates atherosclerosis in mice. Arterioscler Thromb Vasc Biol (2014) 1.45
Mosaic compound heterozygosity of SHOX resulting in Leri-Weill dyschondrosteosis with marked short stature: implications for disease mechanisms and recurrence risks. Am J Med Genet A (2010) 1.43
Osteonecrosis in a patient with Gaucher's disease treated with enzyme replacement. Isr Med Assoc J (2003) 1.41
Uveitis in Gaucher disease. Am J Ophthalmol (2005) 1.39
Factors affecting regression of mitral regurgitation following isolated coronary artery bypass surgery. Eur J Cardiothorac Surg (2005) 1.38
Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol (2014) 1.37
Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis. Nat Med (2013) 1.36
Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cells Mol Dis (2006) 1.34
Pivotal advance: macrophages become resistant to cholesterol-induced death after phagocytosis of apoptotic cells. J Leukoc Biol (2007) 1.33
Functional proteolytic complexes of the human mitochondrial ATP-dependent protease, hClpXP. J Biol Chem (2002) 1.24
White matter lesions in Fabry disease occur in 'prior' selectively hypometabolic and hyperperfused brain regions. Brain Res Bull (2003) 1.23
Modeling a whole organ using proteomics: the avian bursa of Fabricius. Proteomics (2006) 1.22
A PEST deletion mutant of ABCA1 shows impaired internalization and defective cholesterol efflux from late endosomes. J Biol Chem (2005) 1.22
Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012. Drug Saf (2013) 1.22
Ca(2+) regulation of connexin 43 hemichannels in C6 glioma and glial cells. Cell Calcium (2009) 1.20
Phosphorylation of a pest sequence in ABCA1 promotes calpain degradation and is reversed by ApoA-I. J Biol Chem (2003) 1.19
Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies. Clin Ther (2007) 1.18
miR-203 inhibits cell proliferation and migration of lung cancer cells by targeting PKCα. PLoS One (2013) 1.18
miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer. Mol Cancer (2014) 1.17
Regulation of the androgen receptor by SET9-mediated methylation. Nucleic Acids Res (2010) 1.17
The positive allosteric modulator morantel binds at noncanonical subunit interfaces of neuronal nicotinic acetylcholine receptors. J Neurosci (2009) 1.13
Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood Cells Mol Dis (2002) 1.13
Disruption of MHC class II-restricted antigen presentation by vaccinia virus. J Immunol (2005) 1.13
Characterization of human tear proteome using multiple proteomic analysis techniques. J Proteome Res (2005) 1.11
Intramolecular loop/tail interactions are essential for connexin 43-hemichannel activity. FASEB J (2010) 1.10
Compartmentalization of class II antigen presentation: contribution of cytoplasmic and endosomal processing. Immunol Rev (2005) 1.10
ATP-binding cassette transporter G1 and high-density lipoprotein promote endothelial NO synthesis through a decrease in the interaction of caveolin-1 and endothelial NO synthase. Arterioscler Thromb Vasc Biol (2010) 1.10
Construction, gene delivery, and expression of DNA tethered nanoparticles. Mol Vis (2006) 1.10
Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke (2002) 1.10
Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood (2007) 1.09
ProtQuant: a tool for the label-free quantification of MudPIT proteomics data. BMC Bioinformatics (2007) 1.09
Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells Mol Dis (2005) 1.09
Characterization of the stress associated microRNAs in Glycine max by deep sequencing. BMC Plant Biol (2011) 1.08
Antiviral activities of ISG20 in positive-strand RNA virus infections. Virology (2010) 1.08
Gene expression profiling of soybean leaves and roots under salt, saline-alkali and drought stress by high-throughput Illumina sequencing. Gene (2012) 1.08
Functional aberrant expression of CCR2 receptor on chronically activated NK cells in patients with TAP-2 deficiency. Blood (2005) 1.07
Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis. Evid Based Complement Alternat Med (2012) 1.07
An association study of inflammatory cytokine gene polymorphisms in Fabry disease. Eur Cytokine Netw (2006) 1.07
Tc17 cells are capable of mediating immunity to vaccinia virus by acquisition of a cytotoxic phenotype. J Immunol (2010) 1.06
Panax notoginseng reduces atherosclerotic lesions in ApoE-deficient mice and inhibits TNF-alpha-induced endothelial adhesion molecule expression and monocyte adhesion. J Agric Food Chem (2009) 1.06
Getting the right cells to the array: Gene expression microarray analysis of cell mixtures and sorted cells. Cytometry A (2004) 1.05
Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply. Blood Cells Mol Dis (2010) 1.05
TRIM56 is a virus- and interferon-inducible E3 ubiquitin ligase that restricts pestivirus infection. J Virol (2011) 1.05
Serum microRNA 143 and microRNA 215 as potential biomarkers for the diagnosis of chronic hepatitis and hepatocellular carcinoma. Diagn Pathol (2014) 1.04
Let-7a microRNA functions as a potential tumor suppressor in human laryngeal cancer. Oncol Rep (2009) 1.04
Pericardial constriction after cardiac transplantation. J Heart Lung Transplant (2009) 1.04
Minor allele C of chromosome 1p32 single nucleotide polymorphism rs11206510 confers risk of ischemic stroke in the Chinese Han population. Stroke (2010) 1.03
Angiotensin-converting enzyme 2 attenuates atherosclerotic lesions by targeting vascular cells. Proc Natl Acad Sci U S A (2010) 1.03
A pharmacokinetic analysis of a novel enzyme replacement therapy with Gene-Activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease. Blood Cells Mol Dis (2007) 1.03
A novel Bcl-XL inhibitor Z36 that induces autophagic cell death in Hela cells. Autophagy (2009) 1.02
Prevalence of Nontraumatic Osteonecrosis of the Femoral Head and its Associated Risk Factors in the Chinese Population: Results from a Nationally Representative Survey. Chin Med J (Engl) (2015) 1.01
The proteogenomic mapping tool. BMC Bioinformatics (2011) 1.01
De novo sequencing and comparative analysis of the blueberry transcriptome to discover putative genes related to antioxidants. Gene (2012) 1.01
De novo transcriptome of safflower and the identification of putative genes for oleosin and the biosynthesis of flavonoids. PLoS One (2012) 1.01
Pannexin channels in ATP release and beyond: an unexpected rendezvous at the endoplasmic reticulum. Cell Signal (2010) 1.01
Gaucher disease and the clinical experience with substrate reduction therapy. Philos Trans R Soc Lond B Biol Sci (2003) 1.00